๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5 Hangzhou 3 Shanghai 3 Shenzhen 2 Chengdu 1
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing5 Hangzhou3 Shanghai3 Shenzhen2 Chengdu1
All 11 locations
Target enrolment
to

Trials with a site in Beijing

5 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma
NCT06644430Advanced Hepatocellular Carcinoma, Lung Cancer, Oligometastasis, Ablation
Sun Yat-sen University
Observational
470
Beijing
2024-10-04
Recruiting
dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma
NCT06609863Advanced Hepatocellular Carcinoma, Atezolizumab, Bevacizumab, Chemotherapy
Sun Yat-sen University
Not applicable
27
Beijing
2024-10-01
Recruiting
Early Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular Carcinoma
NCT06624098Advanced Hepatocellular Carcinoma, Variceal Bleeding
Sun Yat-sen University
Not applicable
22
Beijing
2024-10-01
Recruiting
Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma
NCT06550921Advanced Hepatocellular Carcinoma, Oligometastasis, Ablation, Anti-PD1 Antibody
Sun Yat-sen University
Not applicable
60
Beijing
2024-08-01
Recruiting
Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma
NCT06323382Advanced Hepatocellular Carcinoma, Anti-PD1/PDL1 Antibody, Bevacizumab
Sun Yat-sen University
Observational
240
Beijing
2021-01-01
Rows per page Showing 1–5 of 5
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

5 of the 5 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 0 have not yet opened recruitment, 0 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 5 studies
PhaseStudiesRecruitingShare
Not applicable3360%
Observational2240%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
Sun Yat-sen University55
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.